Page 159 - Traité de chimie thérapeutique 6 Médicaments antitumoraux
P. 159
6. OXAZOPHORINES CYCLOPHOSPHAMIDE ETANALOGUES 115
EFFETS INDÉSIRABLES
GOREN M.P. et al., dechlorethylation of ifosfamide and neurotoxicity, Lancet, 1986, ii,
1219-1220.
MEANWELL C.A. et al., Avoiding ifosfamide/mesna encephalopathy, Lancet, 1986, ii,
406.
CERNY T. et al., lfosfamide by continuous infusion to prevent encephalopathy, Lancet,
1990, 335, 175.
LEWIS L.D., MEANWELL C.A., lfosfamide pharmacokinetics and neurotoxicity, Lancet,
1990, 335, 175-176.
MARTHALER N.P. et al., lncreased urinary losses of camithine during ifosfamide chemo-
therapy, Cancer Chemother. Pharmacol., 1999, 44,170-172.
AUTRES DÉRIVÉS
MOON K.Y., KWON C.H., N-methylmafosfamide as a chemically stable, alternative pro-
drug of mafosfamide, Bioorg. & Med. Chem. Lett., 1998, 8, 1673-167.
ENGEL J. et al., Glufosfamid, Drugs Fut., 2000, 25, 791-794 ; 2001, 26, 801
